Meeder Asset Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Meeder Asset Management’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,066	Closed	-$23K	–	2455
2021 Q3	$23K	Buy	2,066 +1,490	+259%	+$20.5K	﹤0.01%	1376
2021 Q2	$10K	Buy	+576	New	+$9.27K	﹤0.01%	1710
2020 Q4	–	Sell	-2,522	Closed	-$33K	–	2299
2020 Q3	$33K	Buy	2,522 +151	+6%	+$1.3K	﹤0.01%	1038
2020 Q2	$24K	Buy	2,371 +193	+9%	+$1.77K	﹤0.01%	1097
2020 Q1	$17K	Buy	2,178 +1,730	+386%	+$15K	﹤0.01%	1318
2019 Q4	$4K	Sell	448 -514	-53%	-$2.88K	﹤0.01%	1873
2019 Q3	$6K	Buy	962 +474	+97%	+$3.83K	﹤0.01%	1722
2019 Q2	$8K	Sell	488 -68	-12%	-$1.18K	﹤0.01%	1540
2019 Q1	$9K	Sell	556 -2,149	-79%	-$30.9K	﹤0.01%	1279
2018 Q4	$32K	Buy	2,705 +2,476	+1,081%	+$50.1K	﹤0.01%	928
2018 Q3	$9K	Buy	+229	New	+$6.52K	﹤0.01%	1196

Other funds holding MRNS

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Meeder Asset Management's MRNS Position: Q4 2021 in Review

Meeder Asset Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2021, closing a stake of 2,066 shares — an estimated $23K sold.

Meeder Asset Management first reported a position in MRNS in Q3 2018 and held it in 11 quarters. The position peaked at $33K in Q3 2020. 75 funds tracked by Wall St. Rank hold MRNS as of Q4 2021.

Meeder Asset Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2021 after selling out during the quarter.
Meeder Asset Management sold 2,066 Marinus Pharmaceuticals, Inc shares in Q4 2021, an estimated $23K.
Meeder Asset Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2018 and held it in 11 quarters.
Meeder Asset Management's Marinus Pharmaceuticals, Inc position peaked at $33K in Q3 2020.
75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.